BioSpace News Archive

Bicara Therapeutics announced that it will host a virtual webinar to review the latest clinical trial data for BCA101, a first-in-class EGFR/TGFβ-trap bifunctional antibody designed to deliver superior anti-tumor efficacy with an improved therapeutic window to solid tumors.

Osmol Therapeutics announced that Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd., has joined the Board of Directors of Osmol Therapeutics.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.

Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts.

Sernova Corp. announced it will be presenting at the upcoming H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022, as well as the LifeSci Partners HealthTech Symposium being held September 20-21, 2022.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB).

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.

Annovis Bio, Inc., a late-stage clinical drug platform company addressing neurodegenerative diseases, released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini.

OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced the initiation of dosing in a Phase 2 basket trial evaluating the anti-DLL4/VEGF bispecific antibody navicixizumab, alone or in combination with chemotherapy, in patients with select advanced solid tumors.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients.